Genomics · World No.1 in DNA sequencing

Illumina

The No.1 in DNA sequencing. It supplies sequencers and consumables to research, pharma and diagnostics, with sequencing 92% of revenue. Q4 revenue $1.16B, FCF $931M. DRAGEN hardware acceleration, cloud analytics (ICA) and BioInsight underpin AI drug discovery. The picks-and-shovels layer that makes techbio data.

ILMN Updated Sep 11, 2026 6 AI consumers· 4 recurring

Per the valuechain.wiki graph, Illumina is directly linked to 4 companies (2 supply, 2 revenue relationships) and reaches 74 companies within two hops; the links are backed by 9 dated sources, 4 of them primary filings (as of 2026-09-11).

Annual return · 2026-09-04'21+2.8%'22-46.9%'23-31.1%'24-1.3%'25-1.8%YTD+66.4%
Money inResearch · pharma · diagnostics (sequencing · consumables)Revenue $4.3BAbbott LaboratoriesBio-AI · data (BioInsight · ICA)Tempus AI
IlluminaQ4 2025 revenue $1.16B, FCF $931M
Money outNVIDIAAmazonSemiconductors · devices · components (undisclosed)R&D & capacity expansion (undisclosed)

Financials & Segments

  • Total revenue · Q4 2025 revenue $1.16B, FCF $931M
  • Customer concentration · Sequencing 92%; Billion Cell Atlas.
  • Segments · Sequencing 92% · Data/services

Revenue from

  • Research · pharma · diagnostics (sequencing · consumables) High confidence· Revenue $4.3B · FY2025 · FY2025 revenue (-0.7%); 2026 guidance $4.5-4.6B
    Supplies sequencers and consumables to research, pharma and diagnostics (sequencing 92% of revenue) — the core revenue source where the installed base drives recurring consumable demand.
    Mentions EN consensus (via MarketBeat) Published Jun 1, 2026: Illumina analyst Hold, consensus target ~$124 (2026)
    Confirms EN SEC EDGAR Published Feb 1, 2026: Illumina FY2025 10-K
    Confirms EN Illumina Published Jan 1, 2026: Illumina Billion Cell Atlas accelerates AI and drug discovery
    Mentions KO PharmNews Published May 16, 2023: Illumina completes certification of high-throughput IVD sequencer NovaSeq 6000Dx
  • Abbott Laboratories High confidence
    Illumina supplies the sequencing platform and instruments used by Abbott's acquired Exact Sciences business for its OncoExTra, MRD and MCED tests. Equipment and reagent sales are not disclosed.
    Mentions EN SEC EDGAR Published Mar 23, 2026: ABBOTT LABORATORIES 8-K (2026-03-23)
    Confirms EN SEC EDGAR Published Feb 13, 2026: EXACT SCIENCES CORP 10-K (2026-02-13)
  • Bio-AI · data (BioInsight · ICA) Medium confidence
    AI drug-discovery data via BioInsight and cloud analytics.
    Confirms EN Illumina Published Jan 1, 2026: Illumina Billion Cell Atlas accelerates AI and drug discovery
  • Tempus AI Medium confidence
    Supplies sequencers and consumables to precision-oncology diagnostics firm Tempus — a relationship where rising diagnostic throughput drives recurring consumable revenue.
    Confirms EN Tempus Published Feb 24, 2026: Tempus FY2025 results ($1.27B, +83%)

Pays to

  • NVIDIA High confidence
    Accelerates its DRAGEN secondary-analysis pipeline on NVIDIA GPUs and integrates NVIDIA BioNeMo/RAPIDS/MONAI generative genomics AI (Jan 2025 collaboration).
    Confirms EN Illumina Published Jan 13, 2025: Illumina and NVIDIA collaborate to decode biology
  • Amazon High confidence
    Runs Illumina Connected Analytics and BaseSpace on AWS infrastructure (S3, Glacier), storing and computing petabyte-scale genomic data.
    Confirms EN Illumina Published Jun 1, 2024: Illumina AWS partnership
  • Semiconductors · devices · components (undisclosed) Low confidence
    Semiconductors, optics and instrument parts for sequencers.
    Confirms EN SEC EDGAR Published Feb 1, 2026: Illumina FY2025 10-K
  • R&D & capacity expansion (undisclosed) Low confidence
    R&D and manufacturing capacity.
    Confirms EN SEC EDGAR Published Feb 1, 2026: Illumina FY2025 10-K

Value-chain ripple (2 tiers)

Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.

CompanyChain'21'22'23'24'25YTD
Amazonlead2+2.4-49.6+80.9+44.4+5.2+12
Medtronic plclead2-9.8-22.6+9.6+0.3+24-0.3
Walmart Inclead2+2-0.5+12.9+74+24.5-3.2
Tempus AIlead1····+74.9+9.4
Abbott Laboratorieslead1+30.5-20.7+2.3+4.8+12.9-11.9
Illuminanode+2.8-46.9-31.1-1.3-1.8+66.4
NVIDIAbenef1+125.5-50.3+239+171.2+38.9+23.7
Amazonbenef1+2.4-49.6+80.9+44.4+5.2+12
SanDiskbenef2·····+633
Micron Technologybenef2+24.2-45.9+71.9-1+240.2+256.4
Seagate Technologybenef2+87.5-51.4+69.1+4.1+225.3+209.1
Nan Ya PCBbenef2+110.6-46.7-0.5-38.3+188.2+172.1
Nebius Groupbenef2····+202.2+170.5
Marvellbenef2+84.6-57.5+63.7+83.8-22.8+163.4
Kioxiabenef2····+1082.1+155
Ibidenbenef2+30.4-19.6+51.6-38.6+261+149.3
Lumentumbenef2+11.6-50.7+0.5+60.1+339.1+139.1
Unimicronbenef2+133.5-30.2+35.2-19.7+175.7+138.8
ASE Technologybenef2+38.3-12.8+60.9+10.1+65.6+135.3
Murata Manufacturingbenef2-14-11.7+24.7-16.5+29.9+131.5
Wiwynnbenef2+24.7-22.3+206.4+3.5+64.4+120.2
Astera Labsbenef2····+25.6+86.6
SK hynixbenef2-0.4-25.6+53.9+48.6+361.1+81.6
Corningbenef2+5.9-11.6-1.2+60.6+87.8+77.2
Keysight Technologiesbenef2+56.3-17.2-7+1+26.5+61
Samsung Electronicsbenef2-9-14.2+20.9-26.4+212.9+59.7
Wistronbenef2+7.9+9.7+272.7-1.6+22.7+57.3
Coherentbenef2-10-48.6+24+117.6+94.8+52.7
Delta Electronicsbenef2-3.4+10.4-0.3+59.2+183.8+50.4
Arista Networksbenef2+97.9-15.6+94.1+87.7+18.5+47.9
GE Vernovabenef2····+99+44.4
Pegatronbenef2-5.9+0.6+35.3+21.2-23.8+43
Caterpillarbenef2+16+18.6+25.9+24.7+60.3+42.9
TSMCbenef2+12.1-36.7+42.3+92.6+55.9+41.9
FedExbenef2+0.7-31.6+49.1+13.5+5.1+39.6
onsemibenef2+107.5-8.2+33.9-24.5-14.1+37.4
Cienabenef2+45.6-33.8-11.7+88.4+175.8+37.3
Jabilbenef2+66.4-2.5+87.4+13.3+58.7+36.3
Alchip Technologiesbenef2+14.3-8.7+365.1-18.9+0.8+36.1
Monolithic Powerbenef2+35.5-27.8+79.8-5.6+54.5+35.5
Globalstarbenef2+241.2+14.7+45.9+6.7+96.6+34.9
Analog Devicesbenef2+21-4.9+23.4+8.8+29.8+34.8
Eatonbenef2+46.7-7.2+56.2+39.5-2.8+30.1
Eoptolinkbenef2-10.1-27.7+136.6+197+368.8+29.1
Quanta Computerbenef2+22.2-12.8+254.5+12.7+8.9+28.5
InnoLightbenef2-30.7-18.3+253.7+12+468.1+25.6
Digital Realtybenef2+30.7-41+39.9+35.9-10.1+23.4
Amphenolbenef2+34.4-12.5+30.8+40.7+95.3+22.7
Schneider Electricbenef2+25.9+1.6+25.8+36.1+0.5+20.7
Foxconn (Hon Hai)benef2-5.1+2.8+7.8+80.1+26.9+19.6
Credo Technologybenef2··+46.3+245.2+114.1+18.5
ABBbenef2+23.9+7.3+18.9+39+36.1+18.4
Entergybenef2+17.1+3.6-6.1+56+25.3+18.2
Norfolk Southernbenef2+27.3-15.6-1.6+1.6+25.6+15.6
Colgate-Palmolive Companybenef2+2.1-5.4+3.8+16.6-11+14.4
Cumminsbenef2-1.7+14.1+1.7+48.9+49.4+11
United Parcel Service, Inc.benef2+30-16.2-6-15.9-15.9+8
BlackRockbenef2+29.4-20.4+17.9+29.3+6.6+6
Celesticabenef2+37.9+1.3+159.8+215.2+220.3+5.7
Luxshare Precisionbenef2-11.9-30.2-21.2+58.8+29.3+5.6
Procter & Gamblebenef2+20.5-5-0.9+17.3-12.3+4.5
Amorepacificbenef2-30.1-5.7-18.4+9.9+8.2+4.1
Exelonbenef2+41.5+8.3-14+9.2+20+1.9
King Yuan Electronics (KYEC)benef2+26.7-7.7+132.4+38.6+171-6.7
Vistrabenef2+19.6+5.1+70.7+261.5+17.7-7.2
TE Connectivitybenef2+35.1-27.7+24.6+3.5+61.1-7.3
Recursion Pharmaceuticalsbenef2·-55+27.9-31.4-39.5-11.2
IonQbenef2·-79.3+259.1+237.1+7.4-11.9
Abbott Laboratoriesbenef2+30.5-20.7+2.3+4.8+12.9-11.9
Talen Energybenef2···+214.8+86.1-15.4
Quantum Computing Incbenef2-75.8-55.7-39.5+1712.7-38-21.9
BYD Electronicsbenef2-56.1+16-0.4+60.6-19.4-24.1
D-Wave Quantumbenef2·-85.3-38.9+854.5+211.3-36.6
Nikebenef2+18.7-29-6-29.1-13.8-38.1

YTD as of 2026-09-04 · source: Yahoo Finance

Illumina operates across NASDAQ, Genomics, World No.1 DNA sequencing. It is up +66.4% in 2026. The stock (+66.4%) is ahead of both its demand side (avg +9.4%) and supply side (avg +17.9%). Having run ahead of its chain, it is the first spot to give back if customer numbers fail to follow. Among connected nodes the furthest ahead is NVIDIA (+23.7%) and the furthest behind is Tempus AI (+9.4%). If chain logic explains the gap, the laggard is the next propagation candidate; if not, the link itself deserves a second look. The picks-and-shovels layer that makes techbio data.

Analysis generated from returns as of 2026-09-04

Analyst ratings

Consensus: Buy 2 · Hold 0 · Sell 1 · Avg. target $182 · Price $218.22 (09-04) · Upside -17%

BrokerRatingTargetPublished
Evercore ISIOutperform$200Jul 6, 2026Report
Piper SandlerOverweight$200Jul 1, 2026Report
BarclaysUnderweight$145Jun 24, 2026Report

Evercore ISI, Piper Sandler and Guggenheim all lifted targets to $200 in June-July 2026 on clinical demand recovery, while Barclays stays Underweight, leaving consensus near Hold.

Analyses covering this node


← All companiesMarkdown · JSON

For information only, not investment advice. Content on this site is generated by AI from verified, cross-checked sources and may contain errors.

© 2026 Willow Investments, Inc.Company value-chain data · contact@willowinvt.com